Beximco Pharmaceuticals (BXP) Competitors GBX 34 +1.50 (+4.62%) (As of 11:13 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines BXP vs. PRSR, DX, PINE, MGP, WPC, SOHO, LMI, ADVT, ARR, and SAGAShould you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include Prs Reit (PRSR), DX (Group) (DX), Pinewood Technologies Group (PINE), Medica Group (MGP), Witan Pacific Investment Trust PLC (WPC.L) (WPC), Triple Point Social Housing REIT (SOHO), Lonmin (LMI), AdvancedAdvT (ADVT), Aurora Investment Trust (ARR), and Saga (SAGA). These companies are all part of the "trading" industry. Beximco Pharmaceuticals vs. Prs Reit DX (Group) Pinewood Technologies Group Medica Group Witan Pacific Investment Trust PLC (WPC.L) Triple Point Social Housing REIT Lonmin AdvancedAdvT Aurora Investment Trust Saga Prs Reit (LON:PRSR) and Beximco Pharmaceuticals (LON:BXP) are both small-cap real estate companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Do analysts recommend PRSR or BXP? Prs Reit currently has a consensus target price of GBX 120, indicating a potential upside of 16.05%. Given Prs Reit's stronger consensus rating and higher probable upside, research analysts clearly believe Prs Reit is more favorable than Beximco Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prs Reit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Beximco Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor PRSR or BXP? In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.34 beat Prs Reit's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Prs Reit Neutral Beximco Pharmaceuticals Neutral Does the MarketBeat Community prefer PRSR or BXP? Beximco Pharmaceuticals received 23 more outperform votes than Prs Reit when rated by MarketBeat users. Likewise, 64.67% of users gave Beximco Pharmaceuticals an outperform vote while only 50.00% of users gave Prs Reit an outperform vote. CompanyUnderperformOutperformPrs ReitOutperform Votes8550.00% Underperform Votes8550.00% Beximco PharmaceuticalsOutperform Votes10864.67% Underperform Votes5935.33% Is PRSR or BXP more profitable? Prs Reit has a net margin of 108.08% compared to Beximco Pharmaceuticals' net margin of 12.37%. Beximco Pharmaceuticals' return on equity of 10.99% beat Prs Reit's return on equity.Company Net Margins Return on Equity Return on Assets Prs Reit108.08% 8.78% 2.07% Beximco Pharmaceuticals 12.37%10.99%6.97% Is PRSR or BXP a better dividend stock? Prs Reit pays an annual dividend of GBX 4 per share and has a dividend yield of 3.9%. Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 8.8%. Prs Reit pays out 3,636.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Beximco Pharmaceuticals pays out 3,750.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Which has better earnings and valuation, PRSR or BXP? Beximco Pharmaceuticals has higher revenue and earnings than Prs Reit. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Prs Reit, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrs Reit£53.68M10.58£58.02M£0.11940.00Beximco Pharmaceuticals£43.08B0.00£5.33B£0.08425.00 Which has more risk & volatility, PRSR or BXP? Prs Reit has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Beximco Pharmaceuticals has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Do institutionals and insiders have more ownership in PRSR or BXP? 82.6% of Prs Reit shares are owned by institutional investors. Comparatively, 1.7% of Beximco Pharmaceuticals shares are owned by institutional investors. 7.6% of Prs Reit shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryPrs Reit beats Beximco Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Beximco Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BXP vs. The Competition Export to ExcelMetricBeximco PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£151.68M£1.17B£5.10B£1.39BDividend Yield10.27%3.13%5.04%11.86%P/E Ratio425.00109.9795.621,573.12Price / Sales0.001,919.031,217.19212,245.03Price / CashN/A10.2639.5933.11Price / Book0.003.006.942.79Net Income£5.33B£159.40M£118.89M£154.04M7 Day Performance14.48%-1.14%-1.33%-0.59%1 Month Performance9.11%-3.88%-3.17%7.21%1 Year Performance-17.68%91.17%32.49%94.65% Beximco Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BXPBeximco PharmaceuticalsN/AGBX 34+4.6%N/A-24.4%£151.68M£43.08B425.005,500Gap UpPRSRPrs ReitN/AGBX 103.40+0.6%GBX 120+16.1%+20.4%£567.92M£53.68M936.362Gap UpDXDX (Group)N/AN/AN/AN/A£306.77M£471.20M1,185.0020PINEPinewood Technologies Group2.4272 of 5 starsGBX 321-1.4%GBX 455+41.7%N/A£277.63M£22.62M525.005,334Gap UpHigh Trading VolumeMGPMedica GroupN/AGBX 211flatN/A+0.0%£259.85M£76.98M3,516.671,212WPCWitan Pacific Investment Trust PLC (WPC.L)N/AGBX 397+2.3%N/A+0.0%£242.69M£6.74M69.65190SOHOTriple Point Social Housing REITN/AGBX 60.70-1.1%N/A-2.8%£238.84M£39.84M673.7810Dividend AnnouncementPositive NewsHigh Trading VolumeLMILonminN/AGBX 75.60flatN/AN/A£213.79M£1.34B5.113,066ADVTAdvancedAdvTN/AGBX 140flatN/AN/A£186.48M£15.15M14,000.00209Positive NewsARRAurora Investment TrustN/AGBX 230-0.6%N/A+3.3%£175.47M£56.99M327.26N/ANews CoveragePositive NewsSAGASaga2.2752 of 5 starsGBX 110flatGBX 154+40.0%-12.7%£156.82M£811.70M-103.973,682 Related Companies and Tools Related Companies Prs Reit Competitors DX (Group) Competitors Pinewood Technologies Group Competitors Medica Group Competitors Witan Pacific Investment Trust PLC (WPC.L) Competitors Triple Point Social Housing REIT Competitors Lonmin Competitors AdvancedAdvT Competitors Aurora Investment Trust Competitors Saga Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:BXP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beximco Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Beximco Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
